Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renshen Yangrong Tang
- Development stage
- Unknown
- Lead developer
- Peking University Cancer Hospital & Institute
- Administration
- Oral
01
Overview
Renshen Yangrong Tang (RSYRT) is a traditional Chinese medicine (TCM) herbal formulation composed of 12 herbs, with Ginseng (or Codonopsis pilosula) and Astragalus membranaceus (Huangqi) as the primary active components. Developed for clinical use by the Peking University Cancer Hospital & Institute, it is specifically indicated for the management of cancer-related fatigue in survivors who have completed primary treatment. The formula, which dates back to the 11th-century text 'Taiping Huimin Heji Ju Fang', is designed to correct 'Qi deficiency' and replenish blood. It is typically administered orally as herbal extract granules or a decoction. Clinical studies, including Phase II randomized trials, have demonstrated its potential to significantly alleviate moderate to severe fatigue without serious toxicity.
- Other names
- RSYRT decoctionRenshen Yangrong decoction
02
Targets
NOS3 (eNOS)GAA (Lysosomal acid alpha-glucosidase)P4H (Prolyl 4-hydroxylase subunit alpha-3)SLC16A1 (Mitochondrial Pyruvate Carrier)IMPA1 (Inositol Monophosphatase)
Beyond the preview
Go deeper on Renshen Yangrong Tang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renshen Yangrong Tang.